2022 Deal-Making Snapshot: One Big Deal Didn’t Change The Downward Trends

Amgen/Horizon Buyout Lessened Decline

 
• By Joseph Haas

Even with Amgen’s $27.8bn acquisition of Horizon in mid-December, biopharma M&A volume, total value and average deal value all dropped substantially from 2021.

business documents accounting with calculator and magnifying glass. concept for financial
2022 saw a significant decline in biopharma M&A activity

More from Deals

More from Business